论文信息 - Microbial dysbiosis in bronchiectasis. - 字舞流文

Microbial dysbiosis in bronchiectasis.

John R Hurst | J. Hurst

[1] M. McGuckin,et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. , 2013, JAMA.

[2] J. T. Curtis,et al. An Ordination of the Upland Forest Communities of Southern Wisconsin , 1957 .

[3] W. Hanage. Microbiology: Microbiome science needs a healthy dose of scepticism , 2014, Nature.

[4] N. Karalus,et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial , 2012, The Lancet.

[5] Lior Pachter,et al. Disordered Microbial Communities in Asthmatic Airways , 2010, PloS one.

[6] G. Rogers,et al. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. , 2014, The Lancet. Respiratory medicine.

[7] W. Boersma,et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. , 2013, JAMA.

[8] D. Serisier. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. , 2013, The Lancet. Respiratory medicine.

[9] J. DiNicolantonio,et al. Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.